YmAbs Therapeutics (YMAB)
(Delayed Data from NSDQ)
$14.71 USD
-0.13 (-0.88%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $14.68 -0.03 (-0.20%) 7:58 PM ET
1-Strong Buy of 5 1
F Value D Growth B Momentum D VGM
Balance Sheet
Fiscal Year End for YmAbs Therapeutics, Inc falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 79 | 106 | 182 | 115 | 207 |
Receivables | 22 | 13 | 8 | 0 | 0 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 5 | 7 | 6 | 0 | 0 |
Other Current Assets | 5 | 5 | 7 | 8 | 5 |
Total Current Assets | 111 | 130 | 202 | 122 | 212 |
Net Property & Equipment | 0 | 1 | 2 | 2 | 2 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 3 | 3 | 2 | 0 | 0 |
Deposits & Other Assets | 12 | 6 | 3 | 3 | 0 |
Total Assets | 128 | 141 | 213 | 132 | 216 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 6 | 14 | 14 | 9 | 9 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 13 | 13 | 13 | 8 | 5 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 0 | 0 | 0 | 0 | 0 |
Total Current Liabilities | 20 | 28 | 28 | 20 | 14 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 6 | 3 | 3 | 5 | 2 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 27 | 32 | 33 | 26 | 17 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 558 | 544 | 519 | 392 | 365 |
Retained Earnings | -457 | -436 | -340 | -285 | -166 |
Other Equity | 0 | 1 | 1 | -1 | 0 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 101 | 109 | 180 | 106 | 199 |
Total Liabilities & Shareholder's Equity | 128 | 141 | 213 | 132 | 216 |
Total Common Equity | 101 | 109 | 180 | 106 | 199 |
Shares Outstanding | 43.60 | 43.60 | 43.60 | 40.50 | 39.70 |
Book Value Per Share | 2.32 | 2.51 | 4.13 | 2.61 | 5.01 |
Fiscal Year End for YmAbs Therapeutics, Inc falls in the month of December.
All items in Millions except Per Share data.
3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | -99,999 | 79 | 87 | 88 | 93 |
Receivables | NA | 22 | 19 | 19 | 19 |
Notes Receivable | NA | 0 | 0 | 0 | 0 |
Inventories | NA | 5 | 7 | 5 | 9 |
Other Current Assets | NA | 5 | 2 | 4 | 4 |
Total Current Assets | NA | 111 | 115 | 116 | 124 |
Net Property & Equipment | NA | 0 | 0 | 0 | 1 |
Investments & Advances | NA | 0 | 0 | 0 | 0 |
Other Non-Current Assets | NA | 0 | 0 | 0 | 0 |
Deferred Charges | NA | 0 | 0 | 0 | 0 |
Intangibles | NA | 3 | 3 | 3 | 3 |
Deposits & Other Assets | NA | 12 | 9 | 12 | 9 |
Total Assets | NA | 128 | 129 | 132 | 137 |
Liabilities & Shareholders Equity | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 |
---|---|---|---|---|---|
Notes Payable | NA | 0 | 0 | 0 | 0 |
Accounts Payable | NA | 6 | 8 | 7 | 9 |
Current Portion Long-Term Debt | NA | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | NA | 0 | 0 | 0 | 0 |
Accrued Expenses | NA | 13 | 13 | 16 | 16 |
Income Taxes Payable | NA | 0 | 0 | 0 | 0 |
Other Current Liabilities | NA | 0 | 0 | 0 | 0 |
Total Current Liabilities | NA | 20 | 22 | 24 | 26 |
Mortgages | NA | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | NA | 0 | 0 | 0 | 0 |
Convertible Debt | NA | 0 | 0 | 0 | 0 |
Long-Term Debt | NA | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | NA | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | NA | 6 | 3 | 3 | |
Minority Interest (Liabilities) | NA | 0 | 0 | 0 | 0 |
Total Liabilities | NA | 27 | 29 | 28 | 30 |
Shareholders Equity | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 |
---|---|---|---|---|---|
Preferred Stock | NA | 0 | 0 | 0 | 0 |
Common Stock (Par) | NA | 0 | 0 | 0 | 0 |
Capital Surplus | NA | 558 | 555 | 552 | 549 |
Retained Earnings | NA | -457 | -456 | -449 | -442 |
Other Equity | NA | 0 | 2 | 1 | 1 |
Treasury Stock | NA | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | NA | 101 | 100 | 105 | 108 |
Total Liabilities & Shareholder's Equity | NA | 128 | 129 | 132 | 137 |
Total Common Equity | 0 | 101 | 100 | 105 | 108 |
Shares Outstanding | 43.70 | 43.60 | 43.60 | 43.60 | 43.60 |
Book Value Per Share | 0.00 | 2.32 | 2.30 | 2.40 | 2.47 |